CONMED Corporation

Surgical equipment and consumables stocks tracked by StockStory delivered a strong second quarter, with group revenues beating analysts' consensus estimates by 1.6%. STERIS reported revenues of $1.49 billion, up 7.3% year on year, in line with expectations but with the weakest performance against analyst estimates of the group. Solventum posted revenues of $2.21 billion, up 2.2% year on year, outperforming expectations by 2.5% and delivering the biggest analyst estimate beat among its peers. Zimmer Biomet reported revenues of $2.18 billion, up 4.8% year on year, exceeding expectations by 2%, while CONMED reported revenues of $343.5 million, flat year on year, beating expectations by 1.8%. BD reported revenues of $4.98 billion, up 5.4% year on year, topping expectations by 2%.

Several stocks made notable moves this week following earnings reports and executive appointments. Huron Consulting Group surged 35.8% on Wednesday after reporting second-quarter results that beat analyst expectations for both revenue and profit and raising its full-year outlook. Sherwin-Williams rose 7.5% on Tuesday after stronger-than-expected second-quarter earnings and an increased full-year profit forecast. PROG Holdings fell 4.9% on Wednesday despite beating second-quarter 2026 estimates and raising full-year guidance. CONMED gained 10.5% on Thursday after second-quarter adjusted earnings topped expectations and the company lifted its full-year guidance. Freshworks rose 3.4% on Tuesday following the appointment of Ryan Manning as its new Chief Product and Technology Officer.

Zimmer Biomet reported first-quarter revenues of $2.09 billion, up 9.3% year on year, making it the fastest-growing company among five surgical equipment and consumables stocks tracked. The result exceeded analysts' expectations by 0.9%, and the company also beat earnings per share estimates and full-year EPS guidance. CONMED posted revenues of $317 million, down 1.3% year on year but beating estimates by 2.1%, the largest beat in the group. STERIS reported $1.59 billion in revenues, up 7.3% and in line with expectations, while BD's revenues rose 5.2% to $4.71 billion, topping estimates by 0.8%. Solventum's revenues declined 3.1% to $2.01 billion, surpassing estimates by 1.9% but recording the slowest revenue growth among the peers.

CONMED Corporation announced an expanded indication for its AirSeal Robotic Solution, now cleared for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform. The solution was already indicated for Intuitive's 8 mm round cannulas, and this expansion extends compatibility across the da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. The clearance follows extensive engineering and technical compatibility testing conducted in collaboration with Intuitive. Backed by over 40 clinical studies, the AirSeal Robotic Solution is designed to deliver stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation through robotic ports. President and CEO Patrick J. Beyer said the milestone reinforces confidence in the growth opportunity for the AirSeal portfolio.

CONMED Corporation announced its participation in the Society of Robotic Surgery 2026 Annual Meeting, where Professor Nikhil Vasdev will present results from a clinical trial comparing CONMED's AirSeal Insufflation System to Stryker's PneumoClear Insufflator. The prospective randomized controlled trial of 40 patients undergoing robotic prostatectomy found that the AirSeal arm had fewer significant nociceptive events per recorded hour, 20.7 versus 33.5, with a p-value of 0.041. Shorter procedure times, console times, and less blood loss were also observed in the AirSeal arm. The results were published in JUI Compass in May 2026. CONMED will also host a session on low-pressure insufflation in robotic surgery featuring several surgeons.

Conmed soared 10% in after-hours trading on a report that the medical technology company is exploring options, including a possible sale, amid interest from private equity shops. Conmed is working with advisers as it evaluates its options, according to a Bloomberg report that cited people familiar with the matter. Deliberations are ongoing, and there is no certainty any deal will happen. Conmed, which has a market value of about $1 billion, declined to comment to Bloomberg. The company is set to report second-quarter results on July 29, and its shares have dropped 28% over the past year.

CONMED Corporation announced on June 17, 2026 that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer starting July 15, 2026, succeeding Todd Garner who will remain in an advisory role until November 2, 2026. Gallagher brings nearly three decades of finance leadership experience from healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson. The appointment comes alongside a June 1, 2026 amendment to CONMED's credit agreement that added a US$450,000,000 delayed draw term facility to address its 2.25 percent Convertible Senior Notes due 2026. The company's narrative projects $1.6 billion in revenue and $154.0 million in earnings by 2028, with a fair value estimate of $48.40 per share, representing a 49% upside to its current price. Analysts had previously assumed about 3.5 percent annual revenue growth and US$170.3 million in 2029 earnings, and views on CONMED's risk around rising global healthcare cost controls may shift as the new CFO's priorities become clearer.